Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

Prelude Therapeutics (PRLD) EBIAT (2024 - 2025)

Prelude Therapeutics (PRLD) has disclosed EBIAT for 2 consecutive years, with -$16.5 million as the latest value for Q4 2025.

  • Quarterly EBIAT rose 42.72% to -$16.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$99.5 million through Dec 2025, up 21.76% year-over-year, with the annual reading at -$99.5 million for FY2025, 21.76% up from the prior year.
  • EBIAT hit -$16.5 million in Q4 2025 for Prelude Therapeutics, up from -$19.7 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of -$16.5 million in Q4 2025 to a low of -$34.7 million in Q2 2024.